A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning

Trial Profile

A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Monalizumab (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Acronyms PIRAT
  • Most Recent Events

    • 08 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 30 Sep 2016 Status changed from planning to not yet recruiting.
    • 26 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top